These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Reck M Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737 [TBL] [Abstract][Full Text] [Related]
5. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Lung Cancer. Du L; Herbst RS; Morgensztern D Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829 [TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for the treatment of non-small cell lung cancer. Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Expert Opin Biol Ther; 2016; 16(3):397-406. PubMed ID: 26800463 [TBL] [Abstract][Full Text] [Related]
10. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497 [TBL] [Abstract][Full Text] [Related]
12. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis. El-Osta H; Jafri S Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Tan PS; Aguiar P; Haaland B; Lopes G Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267 [TBL] [Abstract][Full Text] [Related]
14. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Sgambato A; Casaluce F; Gridelli C Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis. Chen R; Hou X; Yang L; Zhao D Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504 [TBL] [Abstract][Full Text] [Related]
17. First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers. Landre T; Des Guetz G; Chouahnia K; Taleb C; Vergnenègre A; Chouaïd C J Cancer Res Clin Oncol; 2020 Feb; 146(2):441-448. PubMed ID: 31686247 [TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies. Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454 [TBL] [Abstract][Full Text] [Related]
20. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]